by The global osteoarthritis therapeutics market size accounted for US$ 8.21 Bn in 2022 and is projected to reach around USD 18.36 Bn by 2032, growing at a CAGR of 8.38% from 2023 to 2032.
Report Summary
The global osteoarthritis therapeutics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the osteoarthritis therapeutics market across the globe.
A comprehensive estimate on the osteoarthritis therapeutics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of osteoarthritis therapeutics during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2625
Osteoarthritis Therapeutics Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 8.9 Billion |
| Market Size by 2032 | USD 18.36 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 8.38% |
| Largest Market | Europe |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Drugs, By Anatomy, By Purchasing Pattern, By Distribution Channel and By Route of Administration |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized osteoarthritis therapeutics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Power Generation Market Size To Cross USD 3.9 Trn By 2032
Osteoarthritis Therapeutics Market Players
The report includes the profiles of key osteoarthritis therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- Abbott Laboratories
- ABIOGEN PHARMA S.p.A
- Ampio Pharmaceuticals Inc.
- Anika Therapeutics Inc.
- Bayer Aktiengesellschaft
- Bioventus
- Eli Lilly and Company.
- Ferring B.V.
- Flexion Therapeutics, Inc.
- GlaxoSmithKline Plc.
- Horizon Therapeutics plc.
- Johnson & Johnson Inc.
- Medivir
- Merck Sharp & Dohme Corp.
- Novartis AG
- OrthogenRx, Inc.
- Pacira Pharmaceuticals, Inc
- Pfizer, Inc.
- PHARMED LTD.
- Regeneron
- Sanofi S.A
- TissueGene Inc.
- Zimmer Biomet Holding
Market Segmentation
By Drugs
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Naproxen
- Aspirin
- Diclofenac
- Ibuprofen
- Viscosupplementation agents
- Corticosteroids
- Hyaluronic Acid Injection
- Analgesics
- Duloxetine
- Acetaminophen
By Anatomy
- Ankle Osteoarthritis
- Hip Osteoarthritis
- Knee Osteoarthritis
- Shoulder Osteoarthritis
- Others
By Purchasing Pattern
- Prescription Drugs
- Over-the-counter Drugs
By Distribution Channel
- Hospital Pharmacies
- Hypermarket & Supermarket
- Online Pharmacies
- Retail Pharmacies
- Others
By Route of Administration
- Parenteral Route
- Topical Route
- Oral Route
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Osteoarthritis Therapeutics Market
5.1. COVID-19 Landscape: Osteoarthritis Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Osteoarthritis Therapeutics Market, By Drugs
8.1. Osteoarthritis Therapeutics Market, by Drugs, 2023-2032
8.1.1. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Viscosupplementation agents
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Corticosteroids
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Hyaluronic Acid Injection
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Analgesics
8.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Osteoarthritis Therapeutics Market, By Anatomy
9.1. Osteoarthritis Therapeutics Market, by Anatomy, 2023-2032
9.1.1. Ankle Osteoarthritis
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Hip Osteoarthritis
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Knee Osteoarthritis
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Shoulder Osteoarthritis
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Osteoarthritis Therapeutics Market, By Purchasing Pattern
10.1. Osteoarthritis Therapeutics Market, by Purchasing Pattern, 2023-2032
10.1.1. Prescription Drugs
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Over-the-counter Drugs
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Osteoarthritis Therapeutics Market, By Distribution Channel
11.1. Osteoarthritis Therapeutics Market, by Distribution Channel, 2023-2032
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Hypermarket & Supermarket
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Retail Pharmacies
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Osteoarthritis Therapeutics Market, By Route of Administration
12.1. Osteoarthritis Therapeutics Market, by Route of Administration, 2023-2032
12.1.1. Parenteral Route
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Topical Route
12.1.2.1. Market Revenue and Forecast (2020-2032)
12.1.3. Oral Route
12.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Osteoarthritis Therapeutics Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.1.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.1.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.1.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.5. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.1.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.6.5. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.1.7.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.1.7.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.1.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.7.5. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.2.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.2.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.2.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.5. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.2.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.8. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.2.10. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.11. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.2.12.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.2.12.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.13. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.2.14.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.2.14.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.15. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.3.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.3.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.3.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.5. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.3.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.7. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.3.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.9. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.3.10.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.3.10.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.10.5. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.3.11.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.3.11.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.11.5. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.4.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.4.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.4.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.5. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.4.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.7. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.4.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.9. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.4.10.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.4.10.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.10.5. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.4.11.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.4.11.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.11.5. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.5.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.5.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.5. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.5.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.7. Market Revenue and Forecast, by Route of Administration (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Drugs (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Anatomy (2020-2032)
13.5.8.3. Market Revenue and Forecast, by Purchasing Pattern (2020-2032)
13.5.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.8.5. Market Revenue and Forecast, by Route of Administration (2020-2032)
Chapter 14. Company Profiles
14.1. Abbott Laboratories
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. ABIOGEN PHARMA S.p.A
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Ampio Pharmaceuticals Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Anika Therapeutics Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Bayer Aktiengesellschaft
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Bioventus
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Eli Lilly and Company.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Ferring B.V.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Flexion Therapeutics, Inc.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. GlaxoSmithKline Plc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
